NCT02816970View on ClinicalTrials.gov

Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

February 28, 2014

Study Completion Date

March 31, 2014

Conditions
Healthy
Interventions
DRUG

Vildagliptin

1 tablet contains 50 mg vildagliptin

DRUG

Vildagliptin

1 tablet contains 50 mg vildagliptin

Trial Locations (1)

11757

Genuine Research Center GRC, Cairo

Sponsors

Collaborators (1)

Eva Pharma
All Listed Sponsors
collaborator

Eva Pharma

INDUSTRY

lead

Genuine Research Center, Egypt

INDUSTRY